Vosevi

Sofosbuvir/velpatasvir/voxilaprevir

Sofosbuvir/velpatasvir/voxilaprevir

Combination drug

Sofosbuvir/velpatasvir/voxilaprevir, sold under the brand name Vosevi, is a fixed-dose combination medication for the treatment of hepatitis C. It combines three drugs that each act by a different mechanism of action against the hepatitis C virus: sofosbuvir, velpatasvir, and voxilaprevir.[2] Vosevi was approved for medical use in the United States and in the European Union in July 2017.[3][4] Vosevi is sold by Gilead Sciences.[citation needed]

Quick Facts Combination of, Velpatasvir ...

References

  1. [1]
    "Liver disease". Health Canada. 9 May 2018. Retrieved 13 April 2024.
  2. [2]
    Childs-Kean LM, Brumwell NA, Lodl EF (2019). "Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C". Infection and Drug Resistance. 12: 2259–2268. doi:10.2147/IDR.S171338. PMC 6662169. PMID 31413603.
  3. [3]
    "FDA approves Vosevi for Hepatitis C". U.S. Food and Drug Administration (FDA) (Press release). 18 July 2017. Archived from the original on 23 July 2017. Retrieved 27 July 2017.
  4. [4]
    "Vosevi EPAR". European Medicines Agency (EMA). Retrieved 24 September 2020.


Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Vosevi, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.